Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 140
Inclusion Criteria
- ACR global functional status class of 1 to 3
- Elevated High-sensitivity (hs) CRP and/or ESR
- Documented evidence of inadequate response tumor necrosis factor (TNF) inhibitors
- ...
- ACR global functional status class of 1 to 3
- Elevated High-sensitivity (hs) CRP and/or ESR
- Documented evidence of inadequate response tumor necrosis factor (TNF) inhibitors
- All subjects must have been receiving treatment with a minimum dose of 15 mg per week of Methotrexate for at least 12 weeks and at a stable dose for 28 days prior to screening. A dose as low as 10 mg Methotrexate is permitted if 15 mg could not be reached, due to toxicity. In Japan, Korea and Taiwan, a minimum dose of 7.5 mg per week is permitted. Additional treatment with Hydroxychloroquine or Chloroquine is permitted, if it is at a dose approved for the treatment of RA and the dose has been stable for at least 28 days prior to screening
- Diagnosis of active Rheumatoid Arthritis (RA) by standard criteria (American Rheumatism association (ARA) [1987] or American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) [2010]) at least 16 weeks prior to screening
- Minimum of 6 swollen and 6 tender joints on a 66/68 joint count at screening and at baseline (Day 1)
Exclusion Criteria
- Elevated liver function tests (LFTs)
- History of or active tuberculosis (TB)
- Active serious infection
- Elevated liver function tests (LFTs)
- History of or active tuberculosis (TB)
- Active serious infection
Summary
- Conditions
- Rheumatoid Arthritis
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Inclusion Criteria
- ACR global functional status class of 1 to 3
- Elevated High-sensitivity (hs) CRP and/or ESR
- Documented evidence of inadequate response tumor necrosis factor (TNF) inhibitors
- ...
- ACR global functional status class of 1 to 3
- Elevated High-sensitivity (hs) CRP and/or ESR
- Documented evidence of inadequate response tumor necrosis factor (TNF) inhibitors
- All subjects must have been receiving treatment with a minimum dose of 15 mg per week of Methotrexate for at least 12 weeks and at a stable dose for 28 days prior to screening. A dose as low as 10 mg Methotrexate is permitted if 15 mg could not be reached, due to toxicity. In Japan, Korea and Taiwan, a minimum dose of 7.5 mg per week is permitted. Additional treatment with Hydroxychloroquine or Chloroquine is permitted, if it is at a dose approved for the treatment of RA and the dose has been stable for at least 28 days prior to screening
- Diagnosis of active Rheumatoid Arthritis (RA) by standard criteria (American Rheumatism association (ARA) [1987] or American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) [2010]) at least 16 weeks prior to screening
- Minimum of 6 swollen and 6 tender joints on a 66/68 joint count at screening and at baseline (Day 1)
Exclusion Criteria
- Elevated liver function tests (LFTs)
- History of or active tuberculosis (TB)
- Active serious infection
- Elevated liver function tests (LFTs)
- History of or active tuberculosis (TB)
- Active serious infection
Tracking Information
- NCT #
- NCT02015520
- Collaborators
- Not Provided
- Investigators
- Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Get Well Soon